Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company based in University Park, Florida. It develops antimicrobial products, including members of the Bisphosphocin class, which act on microbial membranes, and Nu-3, a topical antimicrobial under development for infected diabetic foot ulcers.
No SEC Form 4 filings for $LABT in the last 30 days.
See all $LABT insider activity →Lakewood-Amedex Biotherapeutics redeemed all 127,097 shares of its Series C Preferred Stock for $1.27 million, or $10 per share, from Shakawe Capital. The transaction was completed on November 4, 2026, with payment in cash, and the shares were canceled and returned to treasury.
Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption SARASOTA, Fla., November 5, 2026 – Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) (the “Company”), a clinical-stage biotechnology company advancing a novel cl
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) completed the redemption of its Series C Preferred Stock, simplifying its capital structure and eliminating potential dilution. The company now has no preferred shares outstanding or borrowed money indebtedness, according to the CEO. This move is expected to provide greater financial flexibility for its development programs.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LABT (Lakewood-Amedex Biotherapeutics Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LABT coverage spans corporate actions, technology and financial news.
Lakewood-Amedex Biotherapeutics redeemed all 127,097 shares of its Series C Preferred Stock for $1.27 million, or $10 per share, from Shakawe Capital. The transaction was completed on November 4, 2026, with payment in cash, and the shares were canceled and returned to treasury.
Elimination of preferred stock simplifies capital structure and may reduce dilution risk.
Removal of dilution risk and financing restrictions may be viewed positively, but cash outlay could pressure liquidity.
Positive preclinical data may lift the stock as investors anticipate favorable Phase 2a outcomes.
Positive preclinical results could lift sentiment and drive short‑term buying pressure ahead of upcoming Phase 2a data.
AlphAI scores every news story that mentions LABT with an AI model for sentiment and relevance, and aggregates insider trades from Lakewood-Amedex Biotherapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lakewood-Amedex Biotherapeutics redeemed all 127,097 shares of its Series C Preferred Stock for $1.27 million, or $10 per share, from Shakawe Capital. The transaction was completed on November 4, 2026, with payment in cash, and the shares were canceled and returned to treasury.
Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption SARASOTA, Fla., November 5, 2026 – Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) (the “Company”), a clinical-stage biotechnology company advancing a novel cl
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) completed the redemption of its Series C Preferred Stock, simplifying its capital structure and eliminating potential dilution. The company now has no preferred shares outstanding or borrowed money indebtedness, according to the CEO. This move is expected to provide greater financial flexibility for its development programs.
Lakewood-Amedex Biotherapeutics shared preclinical data showing Nu-3's broad-spectrum activity and low resistance. The company is conducting a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. According to the company, the drug demonstrated rapid activity in tests.
Lakewood-Amedex Biotherapeutics (LABT) reported preclinical data showing its Bisphosphocin compound Nu-8 inhibited up to 97% of E. coli growth in rodents. Aerosol formulations also showed activity against pulmonary infections. The company plans further development to identify a clinical candidate. Nu-3 is in a Phase 2a trial for diabetic foot ulcers, with topline data expected in Q1 2027.
Lakewood-Amedex Biotherapeutics reported positive preclinical data for its Bisphosphocin® compounds, showing up to 97% inhibition of E. coli growth in urinary tract infections and activity against resistant bacteria in pulmonary infections. The company's lead candidate, Nu-3, is in a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. The Bisphosphocin® class aims to combat antibiotic-resistant strains.
Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 22, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of July 30, 2026, there were 2,369,688 shares of
Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.
Lakewood-Amedex Biotherapeutics (LABT) reported Q2 2026 progress, including Nasdaq listing, $7.5M private placement, and Nu-3 Gel Phase 2a trial prep. The company expanded its IP portfolio and appointed David G. Armstrong as Study Chair. LABT aims to advance Nu-3 for infected diabetic foot ulcers, with clinical trial initiation expected soon.
